Eris Lifesciences · NSE: ERIS · BSE: 540596
Q3 FY20 results · Oct–Dec 2019
Eris Lifesciences reported revenue from operations of ₹266.40 crore (up 5.5% from Q3 FY19) and net profit of ₹63.47 crore (down 20.9% from Q3 FY19) for Q3 FY20 (Oct–Dec 2019), on a consolidated basis.
| Item | Q3 FY20 | Q3 FY19 | YoY | Q2 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 266.40 | 252.40 | +5.5% | 284.79 | −6.5% |
| Other income | 8.47 | 10.29 | −17.7% | 5.17 | +63.8% |
| Total income | 274.87 | 262.68 | +4.6% | 289.96 | −5.2% |
| Profit before tax | 72.16 | 89.11 | −19.0% | 102.77 | −29.8% |
| Net profit for the period | 63.47 | 80.20 | −20.9% | 92.71 | −31.5% |
| EPS, basic (₹) | 4.62 | 5.83 | −20.8% | 6.74 | −31.5% |
| Net margin (%) | 23.8 | 31.8 | 32.6 |
| Item | Q3 FY20 | Q3 FY19 | YoY | Q2 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 254.27 | 230.80 | +10.2% | 272.90 | −6.8% |
| Other income | 7.91 | 10.15 | −22.1% | 4.90 | +61.2% |
| Total income | 262.18 | 240.96 | +8.8% | 277.80 | −5.6% |
| Profit before tax | 71.01 | 87.27 | −18.6% | 101.33 | −29.9% |
| Net profit for the period | 62.68 | 78.88 | −20.5% | 91.53 | −31.5% |
| EPS, basic (₹) | 4.55 | 5.74 | −20.7% | 6.66 | −31.7% |
| Net margin (%) | 24.6 | 34.2 | 33.5 |
Consolidated
- Filed with BSE
- 15 Feb 2020, 11:01 IST
- Board meeting
- 14 Feb 2020
- Period
- 01 Oct 2019 to 31 Dec 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 15 Feb 2020, 11:01 IST
- Board meeting
- 14 Feb 2020
- Period
- 01 Oct 2019 to 31 Dec 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE